SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0001564590-18-030022
Filing Date
2018-11-21
Accepted
2018-11-21 16:31:33
Documents
69
Period of Report
2018-09-30

Document Format Files

Seq Description Document Type Size
1 10-Q allo-10q_20180930.htm 10-Q 1537289
2 EX-31.1 allo-ex311_155.htm EX-31.1 15966
3 EX-31.2 allo-ex312_154.htm EX-31.2 15958
4 EX-32.1 allo-ex321_153.htm EX-32.1 9301
  Complete submission text file 0001564590-18-030022.txt   5707457

Data Files

Seq Description Document Type Size
5 XBRL INSTANCE DOCUMENT allo-20180930.xml EX-101.INS 1097562
6 XBRL TAXONOMY EXTENSION SCHEMA allo-20180930.xsd EX-101.SCH 48617
7 XBRL TAXONOMY EXTENSION CALCULATION LINKBASE allo-20180930_cal.xml EX-101.CAL 42797
8 XBRL TAXONOMY EXTENSION DEFINITION LINKBASE allo-20180930_def.xml EX-101.DEF 167285
9 XBRL TAXONOMY EXTENSION LABEL LINKBASE allo-20180930_lab.xml EX-101.LAB 365071
10 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE allo-20180930_pre.xml EX-101.PRE 299632
Mailing Address 210 EAST GRAND AVENUE SOUTH SAN FRANCISCO CA 94080
Business Address 210 EAST GRAND AVENUE SOUTH SAN FRANCISCO CA 94080 (650) 457-2700
Allogene Therapeutics, Inc. (Filer) CIK: 0001737287 (see all company filings)

IRS No.: 823562771 | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 001-38693 | Film No.: 181198541
SIC: 2836 Biological Products, (No Diagnostic Substances)
Office of Life Sciences